Data Foundry

Drug recalls 2025

Gabapentin Capsules — Class II drug recall D-0030-2026

Ongoing recall by The Harvard Drug Group LLC, reported 2025-10-29, distributed nationwide. Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability

Recall numberD-0030-2026
Product typeDrug
ClassificationClass II
StatusOngoing
Voluntary or mandatedVoluntary
Recalling firmThe Harvard Drug Group LLC, Dublin, OH, United States
Recall initiated2025-10-10
Classified2025-10-17
Reported by FDA2025-10-29
DistributedNationwide (US)
Reason classesspecification failure
NDC00904-6665, 00904-6665-61, 00904-6666, 00904-6666-61, 00904-6667, 00904-6667-61
Lot numbersM04950, M04989, M04990, M05056, M05150, M05290, M05312, M05342, M05369, M05386
Expiration dates2026-01, 2026-02, 2026-04, 2026-07, 2026-11, 2027-01, 2027-02

Product

Gabapentin Capsules, USP, 100 mg, 100 Capsules (10 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, USA, NDC 0904-6665-61

Reason for recall

Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0030-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.